Concomitant expression of the CXCR1 or CXCR4 transgene on CAR-NK cells has also demonstrated enhanced migration to CD19+ hematological tumors [320], glioblastoma [321] and ovarian tumors [322]. Here, CD19 is linked to hematopoietic and lymphoid cell neoplasm.